← Leaderboards
Laura J Esserman
University Of California San Francisco
$22,971,436
Attributed
$25,665,269
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$50,696,926 · 10
By mechanism
P01$27,545,878 · 4
U01$12,589,708 · 3
R01$9,088,649 · 1
T32$1,465,691 · 1
R13$7,000 · 1
Top collaborators
- Nola M. Hylton8 shared
- Donald A Berry5 shared
- Alexander D Borowsky3 shared
- Laura J Van'T Veer2 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Katherine Kurshan Matthay$7,757,759
- James L. Sorensen$27,892,556
- Frank Patrick McCormick$56,513,144
- Diane W. Wara$7,985,315
- John Kurhanewicz$27,913,734
Others in their field
Top investigators on “Malignant Breast Neoplasm”
- David Heimbrook · Leidos Biomedical Research, Inc.$347,312,063
- Norman Wolmark · Nsabp Foundation, Inc.$122,067,540
- Walter John Curran · Thomas Jefferson University$97,002,422
- Monica M Bertagnolli · Strang Cancer Prevention Center$84,975,759
- Joseph P. Costantino · University Of Pittsburgh At Pittsburgh$68,847,428
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$60,763,376
Research focus
Malignant Breast NeoplasmWomanMalignant NeoplasmsProgramsTumorResourcesHigh RiskBaseScreeningBiologyBreast Cancer TreatmentLearningBiologicalBreast Cancer Risk FactorData SetImageDiagnosisMolecularBreastDesignTrial DesignClinical TrialsPatient-Focused OutcomesInnovation
Grant awards (45)
WISDOM: A platform to optimize subtype-specific screening and prevention$3,350,587
P01 · FY2025 · CA · contact PI
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes$2,747,550
P01 · FY2025 · CA · contact PI
Project 1: Implementing Risk-based Tools that Incorporate Tumor Biology to Optimize Screening and Prevention$909,958
P01 · FY2025 · CA · contact PI
Core 3: Communications, Administrations, Advocacy, and Project Management$252,672
P01 · FY2025 · CA · contact PI
WISDOM: A platform to optimize subtype-specific screening and prevention$3,537,456
P01 · FY2024 · CA · contact PI
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes$2,641,849
P01 · FY2024 · CA · contact PI
Extending the Diversity, Reach, and Generalizability of the WISDOM Study$1,741,554
R01 · FY2024 · CA · contact PI
Project 1: Implementing Risk-based Tools that Incorporate Tumor Biology to Optimize Screening and Prevention$855,531
P01 · FY2024 · CA · contact PI
Surgical Oncology Training Grant$355,791
T32 · FY2024 · CA · contact PI
Core 3: Communications, Administrations, Advocacy, and Project Management$229,488
P01 · FY2024 · CA · contact PI
RISE UP for Breast Cancer$7,000
R13 · FY2024 · CA · contact PI
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes$2,689,478
P01 · FY2023 · CA · contact PI
Extending the Diversity, Reach, and Generalizability of the WISDOM Study$1,817,596
R01 · FY2023 · CA · contact PI
Surgical Oncology Training Grant$313,954
T32 · FY2023 · CA · contact PI
Core 3: Communications, Administrations, Advocacy, and Project Management$266,572
P01 · FY2023 · CA · contact PI
Extending the Diversity, Reach, and Generalizability of the WISDOM Study$1,861,447
R01 · FY2022 · CA · contact PI
Surgical Oncology Training Grant$303,695
T32 · FY2022 · CA · contact PI
Extending the Diversity, Reach, and Generalizability of the WISDOM Study$1,998,201
R01 · FY2021 · CA · contact PI
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes$1,800,771
P01 · FY2021 · CA · contact PI
Surgical Oncology Training Grant$331,390
T32 · FY2021 · CA · contact PI
Enhancing the Diversity of Participants in the WISDOM Clinical Trial: Practical Challenges and Ethical Implications$161,500
R01 · FY2021 · CA · contact PI
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes$1,845,433
P01 · FY2020 · CA · contact PI
Extending the Diversity, Reach, and Generalizability of the WISDOM Study$1,508,351
R01 · FY2020 · CA · contact PI
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers$654,899
U01 · FY2020 · CA · contact PI
Surgical Oncology Training Grant$160,861
T32 · FY2020 · CA · contact PI
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes$1,954,475
P01 · FY2019 · CA · contact PI
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers$1,012,533
U01 · FY2019 · CA · contact PI
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes$2,124,555
P01 · FY2018 · CA · contact PI
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers$1,257,340
U01 · FY2018 · CA · contact PI
Modeling the Impact of Targeted Therapy Based on Breast Cancer Subtypes$504,776
U01 · FY2018 · CA · contact PI
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes$2,339,503
P01 · FY2017 · CA · contact PI
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers$782,497
U01 · FY2017 · CA · contact PI
Modeling the Impact of Targeted Therapy Based on Breast Cancer Subtypes$401,350
U01 · FY2017 · CA · contact PI
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers$311,925
U01 · FY2017 · CA · contact PI
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers$936,457
U01 · FY2016 · CA · contact PI
Modeling the Impact of Targeted Therapy Based on Breast Cancer Subtypes$420,452
U01 · FY2016 · CA · contact PI
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers$796,788
U01 · FY2015 · CA · contact PI
Modeling the Impact of Targeted Therapy Based on Breast Cancer Subtypes$549,851
U01 · FY2015 · CA · contact PI
Modeling the Impact of Targeted Therapy Based on Breast Cancer Subtypes$586,465
U01 · FY2014 · CA · contact PI
Integrated Biomarkers to Characterize Breast Cancer Risk$555,114
U01 · FY2009 · CA · contact PI
Integrated Biomarkers to Characterize Breast Cancer Risk$756,972
U01 · FY2008 · CA · contact PI
Integrated Biomarkers to Characterize Breast Cancer Risk$753,717
U01 · FY2007 · CA · contact PI
Integrated Biomarkers to Characterize Breast Cancer Risk$812,190
U01 · FY2006 · CA · contact PI
Integrated Biomarkers to Characterize Breast Cancer Risk$796,381
U01 · FY2005 · CA
Integrated Biomarkers to Characterize Breast Cancer Risk$700,001
U01 · FY2004 · CA